AM Pharma

AM‐Pharma is a biopharmaceutical company focused on the preclinical and clinical development of recAP (recombinant Human Alkaline Phosphatase) as a treatment of Acute Kidney Injury (AKI), Ulcerative Colitis (UC), and Hypophosphatasia (HPP). Based on the strong results of the Phase II trials with bovine Alkaline Phosphatase in AKI and UC, AM‐Pharma developed an innovative recombinant form of human Alkaline Phosphatase (recAP), which will be used in ongoing and future trials and for commercialization

Contact

Rumpsterweg 6, 3981 AK, Bunnik
The Netherlands
Phone + 31 (0)30 228 92 22
Fax + 31 (0)30 228 92 20

info@am-pharma.com

www.am‐pharma.com